BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) reported that on July 7, 2026, its board compensation committee approved inducement equity grants of restricted stock units to 37 new employees, covering an aggregate of 83,283 common shares. One-fourth vests on August 16, 2027, then quarterly, subject to continued employment, under a board-adopted equity plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

What This Means

BridgeBio’s approval of 83,283 inducement RSUs for 37 new employees under its existing equity plan h...

Analysis

BridgeBio’s approval of 83,283 inducement RSUs for 37 new employees under its existing equity plan highlights ongoing hiring and stock‑based compensation; investors may weigh routine dilution against capital flexibility from the active ATM shelf and recent insider selling trends.

Key Figures

Inducement RSUs: 83,283 shares New employees: 37 Initial vesting date: August 16, 2027 +3 more

6 metrics

Inducement RSUs 83,283 shares Aggregate restricted stock units granted to 37 new employees

New employees 37 Employees receiving inducement restricted stock unit grants

Initial vesting date August 16, 2027 One‑fourth of RSU shares vest on this date, subject to employment

Plan adoption November 2019 Equity incentive plan originally adopted by board of directors

Plan amendment February 10, 2023 First amendment and restatement of the equity plan

Plan amendment December 13, 2023 Second amendment and restatement of the equity plan

Historical Context

5 past events · Latest: Jul 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 02	Clinical data update	Positive	+3.6%	Post‑hoc ATTRibute‑CM kidney data for acoramidis with favorable outcomes.
Jul 01	Financing agreement	Neutral	+0.1%	Up to $1 billion preferred equity financing to support multiple launches.
Jun 28	Phase 3 trial results	Positive	+2.5%	PROPEL 3 Phase 3 in achondroplasia met primary and key secondary endpoints.
Jun 23	Inducement equity grants	Neutral	+1.1%	RSU inducement awards covering 66,810 shares for 30 new employees.
Jun 22	Clinical data presentation	Positive	+4.0%	Announcement of primary PROPEL 3 results presentation at ICCBH 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clinical, financing, and governance news has generally coincided with modestly positive share reactions.

Regulatory & Risk Context

Active S-3 Shelf · $500,000,000 · Short Interest: 14.82%

Shelf Active

Short Interest

14.82% of float

0% 15% 30%+

moderate as of 2026-06-15 Days to cover: 8.57

Short interest is elevated enough to suggest meaningful two‑sided volatility risk, with positioning that could either amplify rallies or deepen pullbacks depending on news flow.

Active S-3 Shelf Registration 2026-05-07

$500,000,000 registered capacity

An effective $500,000,000 ATM shelf allows the company to issue common stock over time, creating flexibility for capital raises that could dilute existing shareholders if utilized.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"approved equity grants to 37 new employees in restricted stock units for an aggregate"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on July 7, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 37 new employees in restricted stock units for an aggregate of 83,283 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

What inducement equity grants did BridgeBio Pharma (BBIO) approve on July 7, 2026?

BridgeBio Pharma approved restricted stock unit grants covering 83,283 shares of common stock for 37 new employees. According to BridgeBio, these awards were approved by the board’s compensation committee as inducement grants under Nasdaq Listing Rule 5635(c)(4).

What is the vesting schedule for BridgeBio Pharma’s July 2026 inducement RSU grants (BBIO)?

The RSUs vest one-fourth on August 16, 2027, with remaining shares vesting quarterly thereafter. According to BridgeBio, one-twelfth of the remaining units vests each quarter, subject to each employee’s continued employment with the company or its subsidiaries on the applicable vesting dates.

How many employees are covered by BridgeBio Pharma’s July 2026 inducement grants (BBIO)?

The inducement grants cover 37 new employees. According to BridgeBio, the compensation committee approved restricted stock units as a material inducement for these individuals to enter employment with the company, consistent with Nasdaq Listing Rule 5635(c)(4) requirements.

Why did BridgeBio Pharma grant RSUs as inducement awards under Nasdaq Rule 5635(c)(4)?

BridgeBio granted RSUs as inducement awards to new hires under Nasdaq Listing Rule 5635(c)(4). According to BridgeBio, the grants were considered a material inducement for the employees to join the company and were issued under its board-approved equity incentive plan.

What equity plan governs BridgeBio Pharma’s July 2026 inducement RSU grants (BBIO)?

The July 2026 inducement RSUs were granted under a board-adopted equity plan. According to BridgeBio, the plan was adopted in November 2019 and later amended and restated on February 10, 2023 and December 13, 2023 to govern such equity awards.